• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human LFNG Polyclonal Antibody

The antibody against LFNG was raised in rabbit using the Synthesized peptide derived from the Internal region of Human Lunatic Fringe. as the immunogen. This antibody exists as a non-conjugated isotype IgG. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This antibody has been validated on WB, ELISA.

ADC-35164A

The antibody against LFNG was raised in rabbit using the Synthesized peptide derived from the Internal region of Human Lunatic Fringe. as the immunogen. This antibody exists as a non-conjugated isotype IgG. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This antibody has been validated on WB, ELISA.

$167.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-35164A ClonalityPolyclonal
Host SpeciesRabbitTarget NameLFNG
FormLiquidSpecies ReactivityHuman, Mouse, Rat
IsotypeIgGStorage Buffer0.5% BSA and 0.02% sodium azide., Liquid in PBS containing 50% glycerol
Purification MethodThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.ConjugateNon-conjugated
ApplicationELISA, WBStorageUpon receipt

Immunogen Information


Immunogen DescriptionSynthesized peptide derived from the Internal region of Human Lunatic Fringe.Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ8NES3
Background Information
  • Uniprot Id

    Q8NES3

  • Target Species

    Human

  • Target Name

    LFNG

  • Target Full Name

    Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe

  • Target Function

    Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Modulates NOTCH1 activity by modifying O-fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1. Decreases the binding of JAG1 to NOTCH2 but not that of DLL1. Essential mediator of somite segmentation and patterning.

  • Target Involvement

    Spondylocostal dysostosis 3, autosomal recessive (SCDO3)

  • Target Subcellular Location

    Golgi apparatus membrane; Single-pass type II membrane protein.

  • Target Protein Families

    Glycosyltransferase 31 family

  • Target Research Area

    Neuroscience

  • Target Synonyms

    3-N-acetylglucosaminyltransferase lunatic fringe; Beta-1; Beta-13-N-acetylglucosaminyltransferase lunatic fringe; lfng; LFNG_HUMAN; O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase; SCDO3

  • Target Background

    This gene is a member of the glycosyltransferase 31 gene family. Members of this gene family, which also includes the MFNG (GeneID: 4242) and RFNG (GeneID: 5986) genes, encode evolutionarily conserved glycosyltransferases that act in the Notch signaling pathway to define boundaries during embryonic development. While their genomic structure is distinct from other glycosyltransferases, these proteins have a fucose-specific beta-1, 3-N-acetylglucosaminyltransferase activity that leads to elongation of O-linked fucose residues on Notch, which alters Notch signaling. The protein encoded by this gene is predicted to be a single-pass type II Golgi membrane protein but it may also be secreted and proteolytically processed like the related proteins in mouse and Drosophila (PMID: 9187150). Mutations in this gene have been associated with autosomal recessive spondylocostal dysostosis 3.

Inquire Rabbit anti-Human LFNG Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification